Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 4, 2009, Pages 579-597

  Cohen, Marc ^a,b  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Aspirin; Clopidogrel; Coronary artery disease; Coronary intervention; Glycoprotein IIb IIIa antagonists

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FLUINDOSTATIN; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; OMEPRAZOLE; OTAMIXABAN; PACLITAXEL; PLACEBO; PRASUGREL; PRAVASTATIN; RAPAMYCIN; RETEPLASE; SCH 530348; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANTICOAGULATION; ATHEROSCLEROSIS; BARE METAL STENT; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENTIATION; DYSPNEA; EARLY INTERVENTION; GASTROINTESTINAL DISEASE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; MUSCLE NECROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION;

AMERICAN HEART ASSOCIATION; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; MEDICATION ADHERENCE; METALS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; RISK ASSESSMENT; STENTS; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 71049137323     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22021     Document Type: Review

References (170)

1. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intevention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-295.
2. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100:1261-1275.
3. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update. A report from the american heart association statistics committee and stroke statistics subcommittee. Circulation 2008;117:e25-146.
4. Elwood PC. Aspirin: Past, present and future. Clin Med 2001;1:132-137.
5. Chambers S, Yawn R. Drug review-Clopidogrel. Drugs Context 2004;1:87-112.
6. ISIS-2(Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360. (Pubitemid 18205209)
7. AntithromboticTrialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
8. Savage MP, Goldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995;92:3194-3200.
9. CAPRIESteering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
10. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999;21:325-335.
11. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533. (Pubitemid 32772726)
12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
13. Gerschutz GP, Bhatt DL. The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation. Cleve Clin J Med 2002;69:377-378, 380, 382 passim.
14. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420. (Pubitemid 35340537)
15. ADVANCEMI Investigators. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated Addressing the value of facilitated Angioplasty after combination therapy or eptifibatide monotherapy in acute myocardial infarction (ADVANCE MI) trial. Am Heart J 2005;150:116-122.
16. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA 2005;293:1759-1765. (Pubitemid 40491302)
17. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005;26: 2520-2523.
18. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-2835.
19. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903. (Pubitemid 32553358)
20. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966. (Pubitemid 34983245)
21. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol 2002;89:653-661 (Pubitemid 34230559)
22. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 2003;108:1682-1687.
23. Paniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E, Valente S, Giglioli C, Fedi S, Gensini GF, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007;128:143-149. (Pubitemid 47121727)
24. Rozalski M, Boncler M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacol Rep 2005;57:1-13. (Pubitemid 40601536)
25. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832. (Pubitemid 41579803)
26. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POSTSTENTING Study. J Am Coll Cardiol 2005;46:1820-1826. (Pubitemid 41579802)
27. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, Himbert D, Baruch D, Guillin MC, Steg PG. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: A case-control study. J Am Coll Cardiol 2005;45:1753-1756. (Pubitemid 40779851)
28. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49: 2312-2317. (Pubitemid 46891710)
29. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425. (Pubitemid 44522148)
30. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750. (Pubitemid 44648629)
31. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
32. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126.
33. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004;93:456-458.
34. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 2007;154:221-231. (Pubitemid 47069129)
35. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high risk coronary artery disease patients. J Thromb Haemost 2007;5:1839-1847. (Pubitemid 47288940)
36. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Dirschinger J, Dotzer F, Bollwein H, Schomig A. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT-a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Am Heart J 2006;151:1248-1254.
37. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938.
38. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115: 708-716.
39. Zeymer U, Arntz HR, Darius H, Huber K, Senges J. Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): Study rationale and design. Cardiology 2007;108:265-272. (Pubitemid 350126469)
40. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814-1819. (Pubitemid 47236637)
41. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC. Bene- fit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339-1345. (Pubitemid 44436814)
42. Emmons KL, Taylor NR. Contemporary issues in clopidogrel therapy: New evidence shaping clinical practice. Pharmacotherapy 2007;27:553-563.
43. Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007;119:563-570. (Pubitemid 46321504)
44. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after highdose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681-684.
45. Wolfram RM, Torguson RL, Hassani SE, Xue Z, Gevorkian N, Pichard AD, Satler LF, Kent KM, Waksman R. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 2006;97:984-989.
46. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-943. (Pubitemid 43312753)
47. Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, Keltai M, Budaj A, Yusuf S. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J 2005;150:1177-1184.
48. Szuk T, Gyongyosi M, Homorodi N, Kristof E, Kiraly C, Edes IF, Facsko A, Pavo N, Sodeck G, Strehblow C, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007;153:289-295. (Pubitemid 46096860)
49. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 2004;164:2051-2057.
50. Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, Buttner HJ, Neumann FJ. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008;99:174-181.
51. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-1338. (Pubitemid 38387816)
52. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-1902. (Pubitemid 39452606)
53. Wenaweser P, Windecker S, Billinger M, Cook S, Togni M, Meier B, Haeberli A, Hess OM. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol 2007;99:353-356. (Pubitemid 46149554)
54. Svensson L, Aasa M, Dellborg M, Gibson CM, Kirtane A, Herlitz J, Ohlsson A, Karlsson T, Grip L. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: The Swedish Early Decision (SWEDES) reperfusion trial. Am Heart J 2006;151:798 e1-e7.
55. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx- AMI Trial). J Am Coll Cardiol 2007;49:1517-1524. (Pubitemid 46517954)
56. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)- TIMI 34 trial. Am Heart J 2006;152:668-675. (Pubitemid 44419381)
57. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, Tarducci R, Cosmi F, Baldassarre S, Burali A. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST trial. J Am Coll Cardiol 2006;47:522-528.
58. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing trial. JAMA 2007;297:591-602.
59. Dobrzycki S, Mezynski G, Kralisz P, Prokopczuk P, Nowak K, Kochman W, Zuk J, Bachorzewska-Gajewska H, Sawicki Z, Poniatowski B, et al. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results. Kardiol Pol 2006;64:793-799; discussion800-801.
60. Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: An analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 2005;45:1932-1938.
61. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006;47:2364-2373.
62. Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, et al. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative. J Thromb Thrombolysis 2006;21:211-220.
63. Madan M, Radhakrishnan S, Reis M, Paradiso-Hardy FL, Godin-Edgecombe M, Sparling C, Phillips AM, Shanmugasegaram S, Fort S, Naqvi SZ, et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol 2005;95:1295-1301. (Pubitemid 40719859)
64. Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J 2006;151:373-379.
65. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-919. (Pubitemid 46400858)
66. Valencia R, Price MJ, Sawhney N, Lee SS, Wong GB, Gollapudi RR, Banares M, Schatz RA, Teirstein PS. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE Trial). Am J Cardiol 2007;100:1099-1102. (Pubitemid 47404465)
67. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, III, Harrington RA, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-1017. (Pubitemid 44343544)
68. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042-1050. (Pubitemid 44872990)
69. Kao J, Lincoff AM, Topol EJ, Madrid A, M JP, Sawhney N, Teirstein PS. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Catheter Cardiovasc Interv 2006;68:352-356. (Pubitemid 44330670)
70. Kuchulakanti P, Wolfram R, Torguson R, Rha SW, Cheneau E, Clavijo L, Chu WW, Pinnow EE, Canos D, Satler LF, et al. Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy. Cardiovasc Revasc Med 2005;6:154-159. (Pubitemid 41739637)
71. Lev EI, Patel R, Karim A, Kleiman A, Badimon JJ, Kleiman NS. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: An ex vivo human study. Thromb Haemost 2006;95:441-446.
72. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. J Am Coll Cardiol 2007;49:1362-1368. (Pubitemid 46476844)
73. Voeltz MD, Patel AD, Feit F, Fazel R, Lincoff AM, Manoukian SV. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. Am J Cardiol 2007;99:1513-1517. (Pubitemid 46770636)
74. Keeley EC. Abciximab following clopidogrel reduces post-PCI complications in patients with acute coronary syndromes. Nat Clin Pract Cardiovasc Med 2006;3:650-651.
75. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, Steinhubl SR, Smyth SS. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 2007;27:1850-1856. (Pubitemid 47207182)
76. Marmur JD, Mitre CA, Barnathan E, Cavusoglu E. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the evaluation of 7e3 for the prevention of ischemic complications (EPIC) trial. Am Heart J 2006;152:876-881. (Pubitemid 44632954)
77. Fischell TA, Attia T, Rane S, Salman W. High-dose, singlebolus eptifibatide: A safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006;18:487-491. (Pubitemid 44497339)
78. Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-526.
79. Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, Mehran R, Dangas G, Russell ME, Ellis SG, et al. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel- eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol 2005;96:500-505. (Pubitemid 41135874)
80. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-1538.
81. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: Results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006;48:2186-2191.
82. Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari R. Twoyear clinical follow-up after sirolimus-eluting versus baremetal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: Results from the STRATEGY study. J Am Coll Cardiol 2007;50:138-145. (Pubitemid 47002182)
83. Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU, Akgoz H, Ergelen M, Ciloglu F. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels 2006;21:102-107.
84. Heer T, Zeymer U, Juenger C, Gitt AK, Wienbergen H, Zahn R, Gottwik M, Senges J. Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice. Heart 2006;92:1484-1489. (Pubitemid 44578849)
85. Huang R, Sacks J, Thai H, Goldman S, Morrison DA, Barbiere C, Ohm J. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention. Catheter Cardiovasc Interv 2005;65:25-33. (Pubitemid 40604826)
86. Kim W, Jeong MH, Kim KH, Sohn IS, Hong YJ, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006;47:933-938. (Pubitemid 43316007)
87. Lavi S, Gruberg L, Kapeliovich M, Hammerman H, Boulos M, Grenadier E, Aronson D, Markiewicz W, Beyar R. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients. J Invasive Cardiol 2005;17:296-299.
88. Mardikar HM, Hiremath MS, Moliterno DJ, Mathew R, Arora R, Deo D, Hiremath JS, Deshpande NV, Khan A, Joseph J, et al. Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. Am Heart J 2007;154:344 e1-e5.
89. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, et al. Randomized comparison of prasugrel (CS- 747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373. (Pubitemid 40931949)
90. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study. Postgrad Med J 2006;82:404-410. (Pubitemid 43945478)
91. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-2015. (Pubitemid 350106708)
92. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-2932. (Pubitemid 350291199)
93. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF. For the D-I. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non st-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-1851.
94. DISPERSE-2-Investigators. The DISPERSE2 trial: Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome. Circulation 2005;112:U677.
95. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
96. Storey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Price D, Husted S. AZD6140 exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease. Circulation 2006114:698-699.
97. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856.
98. Craft JA, Marsh NA. Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty. Blood Coagul Fibrinolysis 2003;14:719-728.
99. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005;25:2043-2053. (Pubitemid 41416299)
100. Heestermans AA, van Werkum JW, Schomig E, ten Berg JM, Taubert D. Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost 2006;4:1143-1145.
101. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-2247. (Pubitemid 44497506)
102. Nguyen T, Frishman WH, Nawarskas J, Lerner RG. Variability of response to clopidogrel: Possible mechanisms and clinical implications. Cardiol Rev 2006;14:136-142 (Pubitemid 44350384)
103. Schroeder WS, Ghobrial L, Gandhi PJ. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J Thromb Thrombolysis 2006;22:139-150. (Pubitemid 44473565)
104. Smith SM, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P, Storey RF. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 2005;16:340-345.
105. Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost 2005;3:1655-1662.
106. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 2006;27:647-654.
107. Guthikonda S, Lev EI, Kleiman NS. Resistance to antiplatelet therapy. Curr Cardiol Rep 2005;7:242-248.
108. Patrono C, Rocca B. Drug insight: Aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 2007;4:42-50.
109. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5 (Suppl 1):230-237.
110. de Gaetano G, Cerletti C. Platelet function, antiplatelet therapy and
111. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834.
112. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-93.
113. Michelson AD, Frelinger AL III, Furman MI. Current options in platelet function testing. Am J Cardiol 2006;98:4N-10N.
114. Valgimigli M, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo DJ, Sabate M, Ferrari F, Furgieri A, Tumscitz C, et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). rationale for the study and protocol design. Cardiovasc Drugs Ther 2008;22:313-320.
115. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin nonresponders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004;38:353-356.
116. Gachet C, Leon C, Hechler B. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis 2006;36:223-227.
117. Troxler M, Dickinson K, Homer-Vanniasinkam S. Platelet function and antiplatelet therapy. Br J Surg 2007;94:674-682.
118. Almsherqi ZA, McLachlan CS, Mossop P, Deng Y. Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine. Int J Cardiol 2007;114:101-102. (Pubitemid 44802888)
119. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, Iakovou I, Antoniucci D, Grube E, Tamburino C, Di Mario C, Reimers B, Michev I, et al. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: Insights from the TRUE (Taxusin Real-life Usage Evaluation) Study. Int J Cardiol 2006;108:406-407.
120. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31:174-183. (Pubitemid 40605192)
121. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14. (Pubitemid 34059855)
122. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the Americam Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-818.
123. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 2006;19:439-448. (Pubitemid 44511075)
124. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005;45:1157-1164.
125. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251. (Pubitemid 40094733)
126. Serebruany VL. The, "clopidogrel resistance" trap. Am J Cardiol 2007;100:1044-1106
127. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-37. (Pubitemid 36070929)
128. Neubauer H, Günesdogan G, Hanefeld C, Spiecker MAM. Statins impair the antiplatelet effect of clopidogrel - A flow cytometry study. Eur Heart J (Abstr Suppl) 2003;24:193.
129. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
130. Gurbel PA, Lau WC, Tantry US. Omeprazole: A possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;51:261-263.
131. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, III, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-e286.
132. Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernandez-Antolin R, Zenni MZ, Macaya C, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008;99:161-168.
133. Angiolillo DJ, Costa MA, Shoemaker SB, Desai B, Bernardo E, Suzuki Y, Charlton RK, Zenni MM, Guzman LA, Bass TA. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008;101:440-445. (Pubitemid 351210628)
134. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008;121:463-468. (Pubitemid 351174278)
135. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-2564.
136. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950 (Pubitemid 41612296)
137. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106 (Pubitemid 40577905)
138. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159.
139. Steinhubl S, Roe MT. Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovasc Drug Rev .2007;25:188-203. (Pubitemid 47039093)
140. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, Ten Berg JM, Neumann FJ, Bollwein H, Dirschinger J, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004;44:2133-2136. (Pubitemid 39576031)
141. de Gaetano G, Cerletti C. Aspirin resistance: A revival of platelet aggregation tests? J Thromb Haemost 2003;1:2048-2050.
142. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, Berger PB, Steinhubl SR, Topol EJ. Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial. Circulation 2008;118:S-815-a-.
143. Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA. Abstract 3998: Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel medco outcomes study. Circulation 2008;118:S-815-.
144. Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 2006;108:36-42. (Pubitemid 43324904)
145. Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 2006;68:218-224.
146. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, Seidl K, Schroder R, Schneider S, Senges J. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005;26:1971-1977.
147. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-2217.
148. Cohen M, Mahaffey KW, Pieper K, Pollack CV Jr, Antman EM, Hoekstra J, Goodman SG, Langer A, Col JJ, White HD, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006; 48:1346-1354.
149. ASSENT-3Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
150. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-1914. (Pubitemid 32568330)
151. Kini AS, Chen VHT, Krishnan P, Lee P, Kim MC, Mares A, Suleman J, Moreno PR, Sharma SK. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J .2008;156:513-519.
152. Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, et al. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: Design and rationale for the MULTI-STRATEGY trial. Am Heart J 2007;154:39-45.
153. Gurbel PA, Bliden KP, DiChiara J, Herzog C, Cummings C, Dubois BV, Gesheff TB, Tantry US. Late breaking clinical trial: Bivalirudin with and without eptifibatide for elective stenting: A pharmacodynamic study of platelet reactivity in relation to the occurrence of periprocedural myocardial infarction (The CLEAR-PLATELETS-2 study). 2007 July 6-12,2007;Geneva, Switzerland. pO-S-004.
154. Kapur A, Malik IS, Bagger JP, Anderson JR, Beatt KJ, Hall RJC,investigators C. The coronary artery revascularisation in diabetes (CARDia) trial: A prospective, randomised comparison of optimal coronary angioplasty with use of stenting and abciximab recommended versus up to date coronary artery bypass grafting in patients with diabetes mellitus suitable for either intervention Heart 2003;89:550.
155. Laufs U, Nef H, Mollmann H, Custodis F, Bohm M. Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association. Clin Res Cardiol 2008;97:1-11.
156. Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome-study design and rationale. Am Heart J 2005;149:994-1002.
157. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57.
158. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-635.
159. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
160. Bhatt DL. Intensifying platelet inhibition-Navigating between scylla and charybdis. N Engl J Med 2007;357:2078-2081.
161. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008;118:1626-1636.
162. Chattaraj SC. Cangrelor AstraZeneca. Curr Opin Investig Drugs 2001;2:250-255.
163. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 2006;40:925-930.
164. Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002;24:752-765. (Pubitemid 34596944)
165. Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151:689 e1-689 e10. (Pubitemid 43290262)
166. Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M, Le May MR, Stankowski JE, Emanuelsson H, Weaver WD. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety. Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007;154: 702-709.
167. Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs 2007;16:225-229.
168. Serebruany VL. Dyspnoea after AZD6140: Safety first? Eur Heart J 2006;27:1505; author reply1505-1506.
169. Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: The AZD6140 controversy. Int J Clin Pract 2007;61:529-533. (Pubitemid 46271268)
170. Moliterno DJ, Becker RC, Jennings LK, Berman G, Yang B, Strony JT, Veltri E, Harrington RA. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist (SCH 530348) in percutaneous coronary intervention. J Am Coll Cardiol 2007;49.